Comanche Biopharma Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway (ILAP) Steering Group for CBP-4888, an Investigational siRNA Drug Candidate for the Treatment of sFlt1-mediated Preterm Preeclampsia
January 30, 2025 05:00 ET | Source: Comanche Biopharma ILAP aims to…
Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases
January 06, 2025 16:30 ET | Source: Generation Bio Co. Novel programs…